Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05018416 · ClinicalTrials.gov registry record · Phase 2
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
A Phase 2 study, sponsored by Prokidney.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT05018416 is a Phase 2 study that has completed, run by Prokidney. The registered enrollment target is 53 participants.
The verdict
NCT05018416, a Phase 2 study, has completed, sponsored by Prokidney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with Type1 Diabetes Mellitus (T1DM) or Type2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease (CKD).
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2025-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05018416
The ClinicalTrials.gov registry entry for NCT05018416 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT05018416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05018416 about?
NCT05018416 is a clinical study titled "Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)". The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects wit...
What is the current status of trial NCT05018416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2021-07-27. Estimated completion is 2025-05-20.
What interventions are being tested in trial NCT05018416?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05018416?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.